Rubicon Technologies Says On Dec. 16, Co. Entered Into Securities Purchase Agreement

The FDA has issued a partial clinical hold pausing new patient enrollment in Mersana Therapeutics Inc's (NASDAQ: MRSN) UP-NEXT and UPGRADE-A, the company's ongoing clinical trials of UpRi in